Multiple Sclerosis (MS)
... Multiple sclerosis (MS) is an autoimmune disease in which your body’s immune system degrades the myelin sheath covering your nerves. This sheath serves as protection for your nerves and damage to it can lead to communication errors between your central nervous system (consisting of your brain and ...
... Multiple sclerosis (MS) is an autoimmune disease in which your body’s immune system degrades the myelin sheath covering your nerves. This sheath serves as protection for your nerves and damage to it can lead to communication errors between your central nervous system (consisting of your brain and ...
Magnet - VNS therapy
... Patients who have pre-existing swallowing, cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them since there is the possibility that stimulation migh ...
... Patients who have pre-existing swallowing, cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them since there is the possibility that stimulation migh ...
2. Hidradenitis Suppurativa
... dietary factors that elevate insulin and insulin-like growth factor-1 sensitize the FPSU’s androgen receptors, creating the increase in end organ responsiveness that also leads to follicular occlusion. 2. The follicular duct content expands as keratinocytes accumulate and the wall of the follicle ev ...
... dietary factors that elevate insulin and insulin-like growth factor-1 sensitize the FPSU’s androgen receptors, creating the increase in end organ responsiveness that also leads to follicular occlusion. 2. The follicular duct content expands as keratinocytes accumulate and the wall of the follicle ev ...
Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency
... anti-inflammatory properties in patients with cystic fibrosis and other inflammatory pulmonary diseases. There is consistent evidence that macrolide therapy reduces infectious exacerbations, decreases the requirement for additional antibiotics and improves nutritional measures. Because of these posi ...
... anti-inflammatory properties in patients with cystic fibrosis and other inflammatory pulmonary diseases. There is consistent evidence that macrolide therapy reduces infectious exacerbations, decreases the requirement for additional antibiotics and improves nutritional measures. Because of these posi ...
these guidelines are not intended to substitute clinical judgment
... Defibrillator* candidate: History of ventricular fibrillation/tachycardia, or Class II/III with EF < 35% on optimal therapy Cardiac resynchronization* candidate: EKG QRS > 0.12 seconds, EF < 35%, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical thera ...
... Defibrillator* candidate: History of ventricular fibrillation/tachycardia, or Class II/III with EF < 35% on optimal therapy Cardiac resynchronization* candidate: EKG QRS > 0.12 seconds, EF < 35%, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical thera ...
A Debate Over Cause and Treatment Polarize Strategies for Fighting
... can trace the disease from generation to generation (Myslinski.). Individuals with medication conditions, “such as stroke, heart disease, immune dysfunction, and Parkinson's disease,” may be more likely to become depressed as well (Myslinski). All of these, some of these, one of these ...
... can trace the disease from generation to generation (Myslinski.). Individuals with medication conditions, “such as stroke, heart disease, immune dysfunction, and Parkinson's disease,” may be more likely to become depressed as well (Myslinski). All of these, some of these, one of these ...
PRESS RELEASE - AbbVie | Canada
... NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of VENCLEXTA. ...
... NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of VENCLEXTA. ...
Fever, Flashbulbs, Humps, and Spikes - CiteSeerX
... In myasthenia gravis, the aim is to control reversible symptoms, while in giant cell arteritis the major aim is to prevent arterial occlusions or ruptures, which usually cause irreversible tissue damage. Treatment of giant cell arteritis is made more difficult by the fact that these vascular complic ...
... In myasthenia gravis, the aim is to control reversible symptoms, while in giant cell arteritis the major aim is to prevent arterial occlusions or ruptures, which usually cause irreversible tissue damage. Treatment of giant cell arteritis is made more difficult by the fact that these vascular complic ...
ErEctilE Dysfunction: A Patient Quick-Guide to cause, Diagnosis & treatment R
... to deploying the correct use of vacuum therapy are good candidates for more invasive pharmaceutical or surgical treatments. Also, vacuum therapy is the only treatment that is effective when used in conjunction with all other treatments. Possible Side Effects: Temporary bruising (if not used correctl ...
... to deploying the correct use of vacuum therapy are good candidates for more invasive pharmaceutical or surgical treatments. Also, vacuum therapy is the only treatment that is effective when used in conjunction with all other treatments. Possible Side Effects: Temporary bruising (if not used correctl ...
HOM Disease, Symptom, and Treatment Guide
... The lack of resources can be challenging to medical providers who are accustomed to confirming their diagnosis with labs, x-rays and other diagnostic tests. In Haiti, even when the resources are available, few people have the money to pay for labs or other tests. Diagnosis and treatment often is bas ...
... The lack of resources can be challenging to medical providers who are accustomed to confirming their diagnosis with labs, x-rays and other diagnostic tests. In Haiti, even when the resources are available, few people have the money to pay for labs or other tests. Diagnosis and treatment often is bas ...
Malignant airway obstruction: treating central airway
... commonly misdiagnosed. However, a strong indication that symptoms are due to CAO is that they are unresponsive to inhaled steroids and bronchodialators. Other advanced CAO symptoms are related to signs of decreased ventilation such as tachycardia, diaphoresis and increased work of breathing.7,8 Symp ...
... commonly misdiagnosed. However, a strong indication that symptoms are due to CAO is that they are unresponsive to inhaled steroids and bronchodialators. Other advanced CAO symptoms are related to signs of decreased ventilation such as tachycardia, diaphoresis and increased work of breathing.7,8 Symp ...
Acute bronchitis
... not have signs in the chest or severe features (see Table).3 Coloured sputum can result from either viral or bacterial infection,9 and is not an indication for antibiotic therapy unless the patient has COPD, which is outside the scope of this document. Table: Severe features that are associated with ...
... not have signs in the chest or severe features (see Table).3 Coloured sputum can result from either viral or bacterial infection,9 and is not an indication for antibiotic therapy unless the patient has COPD, which is outside the scope of this document. Table: Severe features that are associated with ...
Autonomic “myasthenia”: the case for an autoimmune
... 1. Autoantibodies are present in patients with the disease. This is a key starting point but by itself does not prove that a disease is antibody-mediated. Antibodies that bind to the α3 subunit of ganglionic AChRs have been detected in a substantial fraction (41%) of patients with AAN (4), but signi ...
... 1. Autoantibodies are present in patients with the disease. This is a key starting point but by itself does not prove that a disease is antibody-mediated. Antibodies that bind to the α3 subunit of ganglionic AChRs have been detected in a substantial fraction (41%) of patients with AAN (4), but signi ...
COPD - Lothian Respiratory MCN
... • encourage the use of spacer devices when needed. The correct delivery system is as important as the drug used. ...
... • encourage the use of spacer devices when needed. The correct delivery system is as important as the drug used. ...
MEMO Strep Throat:
... Mode of transmission: Strep throat is a bacterial infection that is usually spread by person-to-person contact through coughing or sneezing. Exposure to a person who has untreated strep throat may pose a risk for acquiring this infection. A person may be a carrier of the strep bacteria without havin ...
... Mode of transmission: Strep throat is a bacterial infection that is usually spread by person-to-person contact through coughing or sneezing. Exposure to a person who has untreated strep throat may pose a risk for acquiring this infection. A person may be a carrier of the strep bacteria without havin ...
Mycobacterium avium-intracellulare Pulmonary Infection in HIV
... regimen for at least 12 months. Although many of the patients used recognized methods for improving pulmonary secretion clearance, there was no systematic regimen used in this population. Four patients were not treated with a multidrug regimen for their MAI pulmonary disease. None of them had consti ...
... regimen for at least 12 months. Although many of the patients used recognized methods for improving pulmonary secretion clearance, there was no systematic regimen used in this population. Four patients were not treated with a multidrug regimen for their MAI pulmonary disease. None of them had consti ...
IntraCare North Hospital
... At the time of my first ECT treatment, I was 49-years-old and was hospitalized due to severe depression, anxiety, suicidal thoughts and random homicidal thoughts. I was uninterested in social activities or my family. I had been on multiple medication trials in the past. I underwent a series of ECT t ...
... At the time of my first ECT treatment, I was 49-years-old and was hospitalized due to severe depression, anxiety, suicidal thoughts and random homicidal thoughts. I was uninterested in social activities or my family. I had been on multiple medication trials in the past. I underwent a series of ECT t ...
Summary of Product Characteristics Boxed Warning: EMBRYO
... Data should be collected regarding the effects of Impavido (Miltefosine) on spermatogenesis and male hormones in patients with leishmaniasis receiving Impavido (Miltefosine) treatment. Evaluations will include semen volume, sperm count, sperm concentration and motility as well as evaluation of tota ...
... Data should be collected regarding the effects of Impavido (Miltefosine) on spermatogenesis and male hormones in patients with leishmaniasis receiving Impavido (Miltefosine) treatment. Evaluations will include semen volume, sperm count, sperm concentration and motility as well as evaluation of tota ...
Pododermatitis Joel D. Griffies, DVM Diplomate American College of
... encephalopathy with this therapy. The patient is re-examined in 7-10 days. If significant improvement is noted, no further infusions are given. Prolonged remissions have been noted after only one infusion. If minimal to no response is noted, the infusions are repeated every 7-10 days for 4 treatment ...
... encephalopathy with this therapy. The patient is re-examined in 7-10 days. If significant improvement is noted, no further infusions are given. Prolonged remissions have been noted after only one infusion. If minimal to no response is noted, the infusions are repeated every 7-10 days for 4 treatment ...
Winter - Fairview Health Services
... be drawn and their frequency are included in each patient’s individualized, interdisciplinary plan of care. • Educate clinicians on the critical need to assess renal health indicators with each skilled nurse visit. This includes: quantity and quality of urine output; fluid balance shifts; alteratio ...
... be drawn and their frequency are included in each patient’s individualized, interdisciplinary plan of care. • Educate clinicians on the critical need to assess renal health indicators with each skilled nurse visit. This includes: quantity and quality of urine output; fluid balance shifts; alteratio ...
CDC Presentation - American Lung Association
... TB program activities • Actively monitor for adverse effects of the new 12 weekly dose INH-RPT regimen through TB programs • Collect information on programmatic issues • Treatment trials are not good predictors of program experience ...
... TB program activities • Actively monitor for adverse effects of the new 12 weekly dose INH-RPT regimen through TB programs • Collect information on programmatic issues • Treatment trials are not good predictors of program experience ...
Treatment-related questions
... within a few days after injection into the skin and within a week after the injection into the lips. Other types of reactions are very rare, but about 1 in 2000 treated patients have experienced localized reactions thought to be of a hypersensitive nature. These have usually consisted of swelling at ...
... within a few days after injection into the skin and within a week after the injection into the lips. Other types of reactions are very rare, but about 1 in 2000 treated patients have experienced localized reactions thought to be of a hypersensitive nature. These have usually consisted of swelling at ...
Treatment procedure: During treatment, RESTYLANE is
... within a few days after injection into the skin and within a week after the injection into the lips. Other types of reactions are very rare, but about 1 in 2000 treated patients have experienced localized reactions thought to be of a hypersensitive nature. These have usually consisted of swelling at ...
... within a few days after injection into the skin and within a week after the injection into the lips. Other types of reactions are very rare, but about 1 in 2000 treated patients have experienced localized reactions thought to be of a hypersensitive nature. These have usually consisted of swelling at ...
Neuroprotective therapies for multiple sclerosis and other
... For this reason, neuroprotection, aimed at preventing axonal, neuronal, myelin, and oligodendrocyte damage and cell death in the presence of this toxic microenvironment is highly pursued in MS and other demyelinating diseases. Neuroprotective strategies target different processes including oxidative ...
... For this reason, neuroprotection, aimed at preventing axonal, neuronal, myelin, and oligodendrocyte damage and cell death in the presence of this toxic microenvironment is highly pursued in MS and other demyelinating diseases. Neuroprotective strategies target different processes including oxidative ...
Skin Therapy Letter: A-Details PowerPoint Presentation
... Early clinical experience suggests that the optimal use of Alefacept may involve two courses. Some patients have shown benefit from receiving longer courses of therapy (treat to clear) than mandated by the FDA in clinical trials (12 weeks) ...
... Early clinical experience suggests that the optimal use of Alefacept may involve two courses. Some patients have shown benefit from receiving longer courses of therapy (treat to clear) than mandated by the FDA in clinical trials (12 weeks) ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.